Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
Funder
  • 27

  • 22

  • 11

  • 7

  • 4

  • 4

  • 3

  • 3

  • 2

  • 2

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Researcher
City
State
Country
Country of Funder
Start Year
Active Year
Similar Projects for

Project

A Label-Free, Many-Parameter Benchtop Platform for Functionally-Preserved, Viable Cancer Stem Cell Isolation and Biomarker Discovery to Probe Urothelial Carcinoma of the Bladder

Funder: National Cancer Institute

Funding period
USD 300 K
Funding amount
Abstract
Nodexus? previously developed NX One system leverages node-pore sensing electrical detection (non- marker-based) and fluorescence-based marker detection of cells in combination with low-shear microfluidic valving for viable cell sorting and single-cell isolation. In this proposal, we highlight a new instrument that integrates our demonstrated node-pore sensing (?NPS?) single-cell isolation with label-free multi-marker screening for the quickly emerging cancer stem cell (CSC) space, efficient biomarker discovery and functional studies for targeted therapy development would be transformative, but easy access to viable, functionally-preserved live single-cells is not possible using any single commercial instrument. While the platform will eventually be applicable across more cancer subtypes, our initial point of entry into this sector focuses on urothelial carcinoma of the bladder (UCB). Urothelial carcinoma of the bladder is the most common malignancy of the urinary tract, with >600,000 living with bladder cancer and ~79,030 new cases and 16,870 deaths per year in the United States. From extensive conversations with experts in the field, we have found critical pain points related to UCB that the Nodexus platform can address. CSCs are a subpopulation within a heterogeneous mixture of cancer cells that have enhanced pro- malignant properties, but the contribution of specific markers to stem cell-like traits and their clinical utility as biomarkers have not been conclusively determined, making targeted therapy for these cells extremely challenging. A better understanding of the molecular mechanisms underlying urothelial CSC regulation and identification of key molecules associated with CSC generation and maintenance are pivotal for the determination of universally accepted, clinically-accurate biomarkers for early cancer detection and monitoring following transurethral resection of bladder tumor (TURBT) as well as the development of effective targeted therapies. The complexity with studying CSCs is immensely increased due to the heterogeneity within tumors and the variance in CSC-like traits and functional importance in different cancer subtypes. Conclusive confirmation of marker-associated functionality will open the door for targeted therapy development. Further studies of comprehensive panels of markers performed simultaneously will provide significant value for downstream studies for conclusive biomarker identification and optimized therapies. Critically, the functional relevance of such markers must be evaluated and understood; this requires being able to comprehensively screen for numerous markers, isolate single-cell populations to unveil masked heterogeneity, and perform downstream functional studies (e.g. growth, invasion, and resistance to chemotherapeutic agents) on these viable, functionally-preserved isolated single-cells. While existing technologies, such as FACS, MACS, and CyTOF have provided tremendous value within the broader space, none provide label-free easy access to extensively characterized, live, functionally preserved single CSCs in a manner that the Nodexus platform will offer.

 
99
Projects
USD 53.0 M
Aggregated funding amount
USD 646 K
Average funding amount
Project list item
Engineering Smart Solutions for Disorders of the Bladder Urothelium

Engineering and Physical Sciences Research Council

 
2019 - 2023
Project list item
Transdifferentiation of fibroblasts to urothelial progenitors for definitive urothelial replacement therapy in non-muscle invasive bladder cancer

Bladder Cancer Advocacy Network to Philip A Beachy, Kris Butalid Prado

USD 300,000
2019 - 2021
Project list item
Role of Fgfr2 signaling in bladder injury and regeneration

National Institute of Diabetes and Digestive and Kidney Diseases to CARLTON MATTHEW BATES

USD 234,750
2019 - 2022
Project list item
[Exploration of novel therapeutic molecules for urothelial cancer based on the molecular subtypes and metabolomics] - Original in Japanese

Japan Society for the Promotion of Science to Norihiko TSUCHIYA, Sei Naito, Toshihiko Sakurai

USD 39,492
2019 - 2022
Project list item
Combatting Bladder Cancer by Inducing Epithelial Turnover

National Cancer Institute to SOMAN N ABRAHAM

USD 203,510
2019 - 2021
Project list item
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)

National Cancer Institute to NOAH M HAHN

USD 656,816
2019 - 2024
Project list item
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma

National Cancer Institute to HIKMAT AL-AHMADIE

USD 410,835
2019 - 2024
Project list item
Clonal evolution and molecular stratification of urothelial carcinoma in situ of the urinary bladder

German Research Foundation to Stefan Garczyk, Nadine Gaisa

 
2019 -
Project list item
The role of a new molecular driver in bladder cancer

National Cancer Institute to DALEY MORERA

USD 45,016
2018 - 2021
Project list item
SPORE in Bladder Cancer

National Cancer Institute to DEAN F. BAJORIN, HIKMAT AL-AHMADIE, MICHAEL STEPHEN GLICKMAN, TIMOTHY AN-THY CHAN, IRINA OSTROVNAYA, DAVID B SOLIT

USD 4,438,686
2018 - 2023
Project list item
Upper tract urothelial carcinoma is non-basal and T-cell depleted

Bladder Cancer Advocacy Network to Panagiotis Vlachostergios

USD 1,700
2018 - 2018
Project list item
Challenging dogma: an alternative non-hierarchical, epigenetically regulated model of the urothelium.

Biotechnology and Biological Sciences Research Council to Jennifer Southgate

USD 605,256
2018 - 2021
Project list item
Challenging dogma: an alternative non-hierarchical, epigenetically regulated model of the urothelium.

Biotechnology and Biological Sciences Research Council to Andrew Feber

USD 468,019
2018 - 2021
Project list item
Multiplex Functional Interrogation of Oncogenic Networks in Bladder Cancer

Congressionally Directed Medical Research Programs to John Lee

USD 633,600
2017 - 2018
Project list item
Improved detection of bladder cancer recurrence using a biophysical biomarker

National Cancer Institute to MICHAEL D HENRY

USD 301,860
2017 - 2020
Project list item
Urothelial Stem Cells

National Institute of Diabetes and Digestive and Kidney Diseases to TUNG-TIEN SUN

USD 2,073,748
2017 - 2021
Project list item
Proteogenomic characterization of muscle invasive bladder cancer to identify mechanisms of resistance and targets for therapy

Bladder Cancer Advocacy Network to Seth P. Lerner, Susan Hilsenbeck, Matthew James Ellis, Keith Syson Chan, Jonathan Michael Levitt, Sung Yun Jung, Anna Malovannaya, Bing Zhang

USD 300,000
2017 - 2020
load more...